NCT05648006 - First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions

Advanced Colorectal Carcinoma

Interventions

BIOLOGICAL

OH2

Oncolytic Type 2 Herpes Simplex Virus

DRUG

Capecitabine

1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks

DRUG

Bevacizumab

Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.

Trial Locations (1)

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing